Voltage-dependent calcium currents were measured by whole-cell recording technique in cultured cerebellar granule neurons from 8 d old rats, in 10 mM BaCI, and with a holding potential of -80 mV. A saturating dose (10 PM) of the dihydropyridine nimodipine reversibly inhibited the maximum current by 25% and the dose dependence showed IC,, close to 50 rink o-Conotoxin GVIA (cgtx, 5 PM) and w-agatoxin IVA (agatx, 200 nM) irreversibly inhibited the current by 17% and by 47%, respectively.
The effect of nimodipine was additive with that of the toxins. The GABA, agonist (+)baclofen, or (-)baclofen (100 PM), reduced the calcium current by 30 t 5%, with a IC,, 4 WM. The effect was mediated by a pertussis toxin-sensitive G-protein.
In cells treated with cgtx during the experiment or preincubated with the toxin for 30 min, the effect of baclofen was significantly reduced. However, the action of baclofen was not confined to cgtx-sensitive channels: application of nimodipine or agatx resulted in a 50% reduction of the baclofen effect as well. In contrast, baclofen inhibited approximately the same amount of current both before and after the increase caused by the dihydropyridine agonist BayK 8644 and did not modify the slow BayK-induced tail current. These results indicate (1) the modulation through GABA, receptors does not clearly discriminate between pharmacologically distinct calcium channels and (2) L-type calcium channels represent an heterogeneous population in these neurons.
[Key words: dihydropyridines, w-conotoxin GVIA, u-agatoxin /VA, GABA, agonist, PTX-sensitive G-protein, calcium current] Multiple types of pharmacologically distinct voltage-dependent calcium channels have been recognized in neurons Aosaki and Kasai, 1989; Regan et al., 1991; Kasai and Neher, 1992) . These channel types differ in the first place in their pharmacological sensitivity to specific ligands, which include dihydropyridines (DHPs) and several invertebrate toxins (McCleskey et al., 1987; Llinas et al., 1989; Hilliard et al., 1992; Mintz et al., 1992) . Molecular cloning has revealed an even greater structural diversity of neuronal calcium channels and an increasing number of functional brain (Y, subunits have been expressed and described (Snutch et al., 1991; Snutch and Reiner, 1992; Ellinor et al., 1993; Sather et al., 1993) . Pharmacological and structural classification still waits for a clearer link to calcium channel physiological functions, such as synaptic transmission and control of neurotransmitter and hormone release. Recent works suggest that in mammalian central neurons and nerve terminals different types of calcium channels coexist (Turner et al., 1992; Takahashi and Momiyama, 1993) and may work in synergy to mediate a specific function (Turner et al., 1993) .
In neurons, a most ubiquitous and widely studied effect is the G-protein mediated inhibition of calcium channels by a variety of neurotransmitters (Hille, 1992; Hescheler and Schultz, 1993) . Since first reports in sensory neurons (Dunlap and Fishbach, 1981) , this effect has been described and interpreted in many different ways (Bean, 1989; Poll0 et al., 1992; Delcour and Tsien, 1993; Kuo and Bean, 1993) , in view of its putative importance in presynaptic inhibition. In peripheral and clonal neurons, the inhibitory action of several neurotransmitters has been shown to affect mainly, if not exclusively, w-conotoxin (cgtx)-sensitive channels Lipscombe et al., 1989; Caulfield et al., 1992; Elmslie et al., 1992; Cox and Dunlap, 1992; Kasai, 1992; Poll0 et al., 1992) , but in central neurons the picture appears more complex. For example, the GABA, agonist baclofen, which produces presynaptic inhibition in hippocampal slice preparations (Nicoll et al., 1990) and inhibits transmitter release in cerebellar granules (Huston et al., 1990) , inhibits both cgtx-and DHP-sensitive calcium currents in hippocampal neurons (Scholz and Miller, 1991) and the P-type calcium current in other central neurons (Mintz and Bean, 1993) .
In cerebellar granule cells, we and other authors have described a high-voltage-activated calcium current which is partially inhibited by baclofen (Wojcik et al., 1990; Marchetti et al., 1991) . This current displays a complex pharmacological profile: it is increased by the DHP agonist BayK 8644, but is only partially sensitive to antagonist DHPs and cgtx. Therefore we have addressed the question of whether these different pharmacological types of channels also perform different functions, for instance they possess different sensitivity to modulation. We have used the GABA, agonist induced modulation as a model of a physiological response and present here a more detailed investigation of the pharmacological components of this current and their selective inhibition by baclofen.
Materials and Methods
Cell culture.
Cerebellar granule cells were prepared from 8 d old rats following the procedure ,f Levi et al. (1984) , -as previously described (Marchetti et al., 1991) . Neurons were maintained in Basal Eagle's culture medium, supplemented with 10% fetal calf serum and 100 kg/ml gentamicin. The concentration of KC1 was elevated to 25 mM to assure longer survival of granule cells (D'Mello et al., 1993) . Cultures were treated with 10 ELM cytosine arabinoside from day 1. Experiments were 
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carried out in cultures between days 5 and 13 in vitro (5-13 DIV). Up to 95% of the cells were identified as granule cells, as confirmed by the following observations: (1) all neurons have similar morphology; (2) the properties of voltage-dependent calcium currents are reproducible; (3) all the cells respond to application of y-aminobutyric acid (GABA) with the activation of a chloride current (Marchetti et al., 1991) ; and (4) there is very little GABA production during time in culture. Electrophysiology. Membrane currents were measured in whole-cell clamp configuration bv a patch-clama L/M EPC7 amolifier (List Electronic, Dar&&tad& Germaiy), as in o;r previous study*( Marchetti et al., 1991) . Electrodes were manufactured from borosilicate glass capillaries (Hilgenberg GmbH, Malsfeld, Germany) and had resistance of 25 MR Voltage stimulation and data acquisition were performed by a 80486 PC through a 16 bit Digidata 1200 interface (Axon Instrument Inc., Foster City, CA). Currents were sampled at a frequency of 80 psec per point. Capacitance transients were minimized by analog compensation. Unless otherwise stated, all currents traces were corrected for leak and residual capacitance transients by a computer generated P/4 protocol. The holding potential was set to -80 mV in all the experiments reported, but less negative holding potentials were also tested. Holding the membrane at -60 mV or less always resulted in a considerable loss of current (up to 50% at -40 mV); the current decreased with a slow time course and took several minutes to reach the new steady-state value. Frequently, this "very slow inactivation" was irreversible. Thus, a holding potential of -80 mV appeared the most suitable condition to record the total calcium current. Moreover, we do not have indications that a less negative holding potential (up to -40 mV) significantly hdBaYK1 04 favored antagonist DHP binding (Marchetti et al., unpublished observations) . Current traces were analyzed with PCLAMP (Axon Instruments Inc.) and SIGMA PLOT (Jandel Scientific, Erkrath, Germany) software. The current traces shown in the figures are averages over 3-12 consecutive sweeps. The current values were obtained averaging at least 20 points at the peak level. Data are given as mean + SD, with the exception of the dose-dependence curves ( Fig The standard physiological saline used in incubation of the toxins contained (in mu) NaCl 135, KC1 5.4, CaCl, 1.8, MgCl, 1, HEPES 5; pH =7.4 with NaOH.
The bath solution was exchanged by gravity (~3 ml/min flow). All tubing were treated by Sigmacote (Sigma Chemical Co., St. Louis, MO) to minimize contamination of containers. Dihydropyridines were made up in 100% ethanol at a concentration of 10 mM and adequately protected from light. Control experiments were performed to verify that the solvent was completely ineffective at this dilution. Toxins were diluted in the bath solution and pipetted directly to the recording chamber in appropriate volumetric amounts to obtain the desired concentration. Nimodipine was usually applied through the perfusion system; however, when toxins were already present in the bath and the flow was stopped, subsequent addition of nimodipine was accomplished by pipetting it to the chamber; in this latter case, the effect of the drug was sometime slower (see Fig. 3C ). Nevertheless, we verified that the percentage of current blocked was the same with both modes of application.
In some experiments, culture were treated with pertussis toxin (200 or 400 rig/ml, Sigma Chemical Co.) in the culture medium for 12-16 hr.
Chemicals. o-Conotoxin GVIA was obtained from Bachem (Bubendorf, Switzerland) and o-agatoxin IVA from Peptides International (Louisville, KY) and Latoxan (Rosans, France). Nimodipine and BayK 8644 were provided by Bayer Italia S.p.a (Milano, Italy). All other chemicals were purchased from Sigma Chemical Co.
Results
Currents were recorded in a 10 mM Ba external solution, but will be referred to as "calcium current," as in previous work (Marchetti et al., 1991) . This current was identified as a highvoltage-activated calcium current on the basis of the following properties: it activated between -40 and -30 mV and attained a maximum amplitude at + 10 or +20 mV, it was reduced to approximately 50% when barium was equimolar substituted with calcium and it was completely blocked by 50 FM Cd2+, with Ic,, = 1.22 PM.
Effect of dihydropyridines
A saturating dose (10 FM) of the DHP antagonist nimodipine inhibited the calcium current by 25 ? 3% (mean ? SD, n = 46) (Fig. lA,B) . The dose dependence of nimodipine inhibition showed an IC,, close to 50 nM (Fig. 1C) . The effect of nimodipine was completely reversible following wash, but the recov- The agonist DHP BayK 8644 caused an increase of the current, which was much more pronounced at low membrane potential. In the presence of 1 pM BayK, the current at -10 mV increased by up to 300% of control value, while the current at +lO mV increased by 130 ? 50 % (mean -t SD, n = 12). This effect resulted in a shift of the potential value at which the current is half activated (Marchetti et al., 1991) . To determine the dose-dependence curve, the increase was evaluated at a membrane potential of + 10 mV, for consistency with other conditions. The dose dependence of BayK effect extended over 5 Log units and could not be approximated by an occupancy model with a single binding site. Instead, as previously proposed (Brown et al., 1986) , a double-site model could adequately fit the results. The two independent sites postulated by this model showed IC,, of 1 nM and 300 nM respectively (Fig. ID) .
Effect of w-conotoxin GVIA Cgtx, fraction GVIA (5 PM), inhibited the total calcium current by 17 + 2% (mean ? SD, n = 14) ( Fig. 2A) . The effect of this dose of toxin was complete in < 1 min and was irreversible, despite prolonged wash. In other experiments, cells were pretreated with 5 FM cgtx for 30 min in standard physiological saline; in these cells, further acute application of cgtx to the bathing solution did not produce any reduction of the current, indicating that all sites were occupied and irreversibly bound by nimodipine exerts its effect on a channel type distinct from that the toxin.
blocked by agatx.
The effects of the nimodipine and cgtx were approximately additive: the reduction caused by cgtx was independent of the presence of DHP and the average combined effect was 43 ? 5% (mean * SD, n = 8) (Fig. 2B) . In cells chronically treated with 5 pM cgtx for 30 min, nimodipine inhibited 32 & 11%
(mean + SD, n = 6) of the residual current.
The effects of cgtx and agatx showed partial additivity (Fig.  4) . With respect to the control current (the current before any treatment), the combined effect of the two toxins reduced the current by 56 ? 6% (mean ? SD, n = 5).
Effect of w-agatoxin NA Bath application of either 100 or 200 nM o-agatoxin IVA (agatx) depressed the calcium current by 47 f 6% (mean + SD, n = 22) and these doses can be taken as saturating (Fig. 3A,B) . A dose of 50 nM agatx depressed the current by 21 + 7% (mean ? SD, n = 4), while lower doses failed to produce any detectable effect. The effect of the higher doses developed with time constant (T,,) of 40 ? 11 set (n = 7). Recovery was not observed despite prolonged wash, and, different from P-type calcium channels in cerebellar Purkinje neurons , depolarizing prepulses to very positive potential (up to 100 mV) failed to determine any release of the block.
In the presence of the three antagonists, a resistant current was present and was in the range of 20-30% of the total current. This residual current was not investigated further, but did not show major differences in activation and inactivation kinetics from the other components and it was completely suppressed in the presence of 50 FM Cd2+.
Effect of baclofen
The effect of agatx was additive, at a good approximation, with that of nimodipine, as indicated by the fact that nimodipine blocked the same amount of current both before and after agatx application (Fig. 3C) . A similar result was obtained in six cells. Therefore, different from recent results in other preparations (Brown et al., 1994) , our data suggest that a dose of 10 pM Application of ( + )baclofen caused a fast, quickly reversible, but largely incomplete reduction of the calcium current, which was accompanied by a moderate kinetic slowing (Fig. 5) . Baclofen did not affect the baseline current and the resting conductance in these conditions, as shown in the raw records of Figure 5A . The dose dependence of the effect of baclofen showed an IC,, equal to 4 pM and a saturating dose (100 FM) inhibited 35 ? 9 pA of the current (30 + 5%, mean ? SD, IZ = 36) (Fig. 5C ). Quantitatively similar results were obtained with (-)baclofen: in six cells, 100 pM of the racemic compound inhibited the current by 29 t 2%, and the same dose of (-)baclofen inhibited the current by 28 k 2% (mean k SD). When GTP was not present in the recording pipette, baclofen was completely inef- fective (n = 3). Also, after incubation with pertussis toxin (PTX), the effect of baclofen was almost totally prevented (n = 8) (Fig. 5D ). These observations indicate that baclofen modulates the calcium current through a PTX-sensitive G-protein.
Combined effects of baclofen and the .blockers In the presence of cgtx (acute treatment with 5 FM), the effect of baclofen was significantly reduced: in eight cells, the current inhibited by baclofen was 39 + 8 pA in control and 19 + 5 pA (1.5 + 3% of the initial current) in the presence of cgtx @ < 0.01). Cgtx had hardly any effect in the presence of baclofen: in six cells, after addition of baclofen to the bath, cgtx blocked 5 + 4 pA of the current (3 ? 2% of the initial current) with p < 0.01 with respect to the average control inhibition caused by this toxin (22 ? 8 pA, n = 15) (Fig. 6A,B) . However, the cgtx-sensitive current was always smaller than the baclofen-inhibited fraction of the current and this indicated that the effect of baclofen was not confined to cgtx-sensitive channels. Also, in cells pretreated with 5 pM cgtx for 30 min (chronic treatment), a significant inhibition (17 + 7 pA equal to 15 f 4% of the residual cgtx-resistant current, n = 11) was still observed (Fig. 60) .
The cgtx-insensitive, baclofen-sensitive current revealed a complex composition, because it appeared to be blocked by both agatx and nimodipine. The actions of nimodipine and baclofen were not additive, but there was a significant overlap: the combined application of nimodipine and baclofen was more effective than nimodipine or baclofen alone, but less effective than the sum of the effects of the two drugs when applied separately (Fig.  6C) . In 11 cells, the current inhibited by baclofen was 36 ? 8 pA in control and 19 + 7 pA in the presence of l-10 pM nimodipine (p < 0.01). In addition, in cells pretreated with cgtx and in the presence of nimodipine, the effect of baclofen was completely suppressed (Fig. 60) .
The current inhibited by baclofen was also significantly reduced in the presence of agatx (Fig. 7A,B) : in nine cells, baclofen suppressed 30 r+ 7 pA of the current in control and 13 + 1 pA in the presence of agatoxin (p < 0.01). In three cells preincubated with 200 nM agatx for 30 min, baclofen inhibited 16 + 6 pA (p < 0.01 with respect to the average control inhibition; Fig. 7C ).
All the results are summarized in Figure 70 .
Combined effects of baclofen and BayK
In contrast with nimodipine, baclofen did not affect the BayKmodified calcium current. This is shown by the following observations: baclofen inhibited the same amount of current both before and after the enhancement caused by BayK (Fig. 8A,B ) and baclofen did not affect the slow BayK-induced tail current (Fig. SC) . A similar result was obtained when the DHP agonist was applied in the presence of baclofen (Fig. 80) : the current increased to a value lightly smaller than that reached with BayK applied in control condition, due to the block of BayK-insensitive channels, but the slow tail current displayed a comparable amplitude. This result was confirmed in 10 cells. This was also true at lower doses of the agonist (10 nM>, that is, in the range of high affinity constant (n = 10).
Discussion
The calcium current of cerebellar granule cells is maximally inhibited by nimodipine by 25%, by cgtx by 17%, and by agatx by 47%. These percentages represent the average values obtained in a significant number of trials on more than 200 cells in the same culture conditions. No correlation with the age of the culture was detected during the period of investigation (5-13 day in vitro, DIV). The first question addressed by the present work is whether these pharmacological agents block calcium channels selectively or they target mixed populations of channels. The existence of mixed populations has been postulated frequently and, in particular, it has been suggested that a high dose of antagonist DHPs might block different types of calcium channels (Plummer et al., 1989; Regan et al., 1991; Brown et al., 1994) . The dose dependence of nimodipine action presented in Figure 1 C contrasts with this possibility because the inhibition caused by the maximum dose tested (10 pM) was not signifi-3 0 2 4 6 01234 t(min)
cantly different from that caused by 1 pM. Moreover, the effect of nimodipine was additive with both that of cgtx and agatx. On the other hand, recent structural analysis suggests that the three classes here identified as cgtx-, DHP-, and agatx-sensitive channels do not represent homogeneous population of channels, but constitute "families" or "super families" with significant pharmacological and functional diversities (Snutch et al., 1990; Snutch and Reiner, 1992) . In particular, the existence of at least two types of DHP-sensitive neuronal calcium channels, as well as isoforms generated by alternative splicing (Snutch and Reiner, 1992) , together with increasing evidences of multiple DHP-binding sites (Brown et al., 1986; Tang et al., 1993) and both functional (Forti and Pietrobon, 1993) and pharmacological diversity (Plummer et al., 1989; Regan et al., 1991; Brown et al., 1994) furnish a picture of significant variation within the DHP-sensitive channel class. This might explain the differences in the interaction of nimodipine and BayK with calcium channels reported here. For example, in contrast with the results obtained with BayK (Fig. lo) (Fig. 1C) or -50 mV (Marchetti et al., unpublished the average value of the combined inhibition a partial overlap observations). cannot be ruled out completely. A similar discussion applies to agatx-sensitive channels. In cerebellar granule cells, agatx-sensitive channels differ in many respects from the P-type channels described in cerebellar Purkinje cells (Llinas et al., 1989; Mintz et al., 1992; Usowicz et al., 1992) . First, at low (<50 nM) concentrations, agatx was virtually ineffective on these currents, at least in the time course of a typical experiment. Second, the block by higher doses could not be reversed by depolarizing pulses, a property which has been well documented for P-type channels . Therefore these channels may be a different subtype belonging to the "non-L" super family, possibly similar to the recently proposed Q-type channels Randall et al., 1993; Sot Neurosci Abstr 19:1478) . Finally, the action of the agatx was apparently additive with that of cgtx (Fig. 4) , but from
The second main question addressed by this work is whether the modulatory effect of baclofen is confined to a pharmacologically identified class of channel.
The action of baclofen is mediated by a PTX-sensitive G-protein, in agreement with previous observations in sensory (Dolphin and Scott, 1987) and central neurons (Sah, 1990; Mintz and Bean, 1993) , including cerebellar granule cells (Huston et al., 1993) . Similar to other neurotransmitters (Marchetti et al., 1986; Dolphin and Scott, 1987; Kasai and Aosaki, 1989; Elmslie et al., 1990) , baclofen also affected the current kinetics, but a voltage dependence of the effect (Bean, 1989) was unclear by analysis of the current-voltage relationship.
Although baclofen affected the current only partially, it appeared to target different channel types. This result differs from previous reports in peripheral and clonal neurons Lipscombe et al., 1989; Caulfield et al., 1992; Cox and Dunlap, 1992; Elmslie et al., 1992; Kasai, 1992; Poll0 et al., 1992) and is in agreement with the work of Scholz and Miller (199 l) , who showed that, in pyramidal hippocampal neurons, the baclofen-induced inhibition of the calcium current was more pronounced than that caused by cgtx, and with that of Mintz and Bean (1993) , who reported that baclofen modulates P-type calcium channels in central neurons.
If we interpret the action of baclofen as related to the presence of a specific modulatory site on the channel, this site should be present on cgtx-sensitive channels (as in peripheral and clonal neurons), but also in subsets of DHP-and agatx-sensitive channels, as both nimodipine and agatx partially occluded subsequent responses to baclofen. Furthermore, the result that acute exposure to nimodipine after chronic treatment with cgtx totally prevented the action of baclofen (Fig. 60 ) might suggest that chronic treatment with cgtx blocks a class of channels, which includes also those targeted by both baclofen and agatx. However, this hypothesis was not tested directly in the present work.
Another observation is the distinct behavior of DHP agonist and antagonist. If baclofen affects L-channels, as unequivocally proved by the nimodipine experiments, one would expect that it would also decrease the amplitude of the BayK-induced slow tail current. However, this was not the case and this observation can have different explanations. First, one might suppose that BayK modifies the target channel, making it resistant to G-protein induced modulation. The effect of dihydropyridines has been modelled in many different ways (Hess et al., 1984; Brown et al., 1986; Lacerda and Brown, 1989) , of which a very popular one is the "modes" hypothesis (Hess et al., 1984) . Following the indication of this attractive scheme, one might suppose that baclofen is not capable to modulate L-channels that are in mode 2, the BayK-favored mode. This is possible, but in partial contrast to other two observations, which suggest instead that BayK and baclofen affect two different channel types. First, the amplitude of the current blocked by baclofen was the same before and after BayK treatment and, second, when baclofen was applied first and followed by BayK, the amplitude of the slow tail current was comparable with that induced by BayK in control. Then, we also propose the different explanation that the DHPsensitive calcium channels which are equipped with a modulatory site for baclofen-activated G-protein are not sensitive to BayK, but only to nimodipine. Any detailed description of these different L-type channels is premature and necessarily speculative, but matches with the hypothesis of different DHP binding sites, which might be differentially distributed in the subclasses of L-type channels, belonging to the L super family.
In conclusion, our results suggest that, in cerebellar granule cells, (1) cgtx-sensitive channels, which represent a minority, possess a modulatory site for baclofen-activated G-protein; (2) DHP-sensitive calcium channels are an heterogeneous population and only a subclass of these channels possesses the modulatory site; and (3) also agatx-sensitive channels are an heterogeneous population because only a subclass of these channels possesses a modulatory site for baclofen. In view of these considerations, we suggest that a purely pharmacological classification, using the presently available specific blockers, may be inadequate to classify native central neuron calcium channels with respect to their physiological function.
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